HS Pipeline Watch: First Patient Dosed in Phase 2 Trial of AVTX-009; Topline Data Expected in 2026
The first patient has been dosed in Avalo Therapeutics, Inc.’s Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. The LOTUS Trial is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial with two AVTX-009 dose regimens […]